Cargando…

Immune Response to Sipuleucel-T in Prostate Cancer

Historically, chemotherapy has remained the most commonly utilized therapy in patients with metastatic cancers. In prostate cancer, chemotherapy has been reserved for patients whose metastatic disease becomes resistant to first line castration or androgen deprivation. While chemotherapy palliates, d...

Descripción completa

Detalles Bibliográficos
Autores principales:	Thara, Eddie, Dorff, Tanya B., Averia-Suboc, Monica, Luther, Michael, Reed, Mary E., Pinski, Jacek K., Quinn, David I.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2012
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3712699/ https://www.ncbi.nlm.nih.gov/pubmed/24213318 http://dx.doi.org/10.3390/cancers4040420

Ejemplares similares

Sipuleucel-T: immunotherapy for advanced prostate cancer
por: Olson, Brian M, et al.
Publicado: (2011)

Phase Ib study of patients with metastatic castrate-resistant prostate cancer treated with different sequencing regimens of atezolizumab and sipuleucel-T
por: Dorff, Tanya, et al.
Publicado: (2021)

Phase 2 Trial of Monoamine Oxidase Inhibitor Phenelzine in Biochemical Recurrent Prostate Cancer
por: Gross, Mitchell E., et al.
Publicado: (2020)

A Phase II Trial of a Combination Herbal Supplement for Men with Biochemically Recurrent Prostate Cancer
por: Dorff, Tanya B., et al.
Publicado: (2014)

Interdisciplinary Critique of Sipuleucel-T as Immunotherapy in Castration-Resistant Prostate Cancer
por: Huber, Marie L., et al.
Publicado: (2012)

Management Options in Advanced Prostate Cancer: What is the Role for Sipuleucel-T?
por: Bitting, Rhonda L., et al.
Publicado: (2011)

Perspectives on sipuleucel-T: Its role in the prostate cancer treatment paradigm
por: Gulley, James L., et al.
Publicado: (2015)

Neoadjuvant sipuleucel-T induces both Th1 activation and immune regulation in localized prostate cancer
por: Hagihara, Katsunobu, et al.
Publicado: (2018)

The Lack of Predictors for Rapid Progression in Prostate Cancer Patients Receiving Sipuleucel-T
por: Ng, Laura, et al.
Publicado: (2013)

Moving on From Sipuleucel-T: New Dendritic Cell Vaccine Strategies for Prostate Cancer
por: Sutherland, Sarah I. M., et al.
Publicado: (2021)

Targeted treatment of metastatic castration-resistant prostate cancer with sipuleucel-T immunotherapy
por: Mulders, Peter F., et al.
Publicado: (2015)

Factors Associated With Use of Sipuleucel-T to Treat Patients With Advanced Prostate Cancer
por: Caram, Megan E. V., et al.
Publicado: (2019)

Recurrent Bilateral Strokes in a Patient Treated With Sipuleucel-T for Prostate Cancer
por: Gill, Jashan, et al.
Publicado: (2021)

Combination Treatment with Sipuleucel-T and Abiraterone Acetate or Enzalutamide for Metastatic Castration-Resistant Prostate Cancer: STAMP and STRIDE Trials
por: Antonarakis, Emmanuel S., et al.
Publicado: (2023)

Pre-existing immune status associated with response to combination of sipuleucel-T and ipilimumab in patients with metastatic castration-resistant prostate cancer
por: Sinha, Meenal, et al.
Publicado: (2021)

Analysis of Circulating Immune Biomarkers by Race in Men With Metastatic Castration-Resistant Prostate Cancer Treated With Sipuleucel-T
por: Hawley, Jessica E, et al.
Publicado: (2021)

Sipuleucel-T in the treatment of prostate cancer: an evidence-based review of its place in therapy
por: Graff, Julie N, et al.
Publicado: (2014)

IL-7 expands lymphocyte populations and enhances immune responses to sipuleucel-T in patients with metastatic castration-resistant prostate cancer (mCRPC)
por: Pachynski, Russell K, et al.
Publicado: (2021)

Sipuleucel-T immunotherapy for castration-resistant prostate cancer. A systematic review and meta-analysis
por: Kawalec, Paweł, et al.
Publicado: (2012)

Activated Lymphocyte Recruitment Into the Tumor Microenvironment Following Preoperative Sipuleucel-T for Localized Prostate Cancer
por: Fong, Lawrence, et al.
Publicado: (2014)

Videos of Sipuleucel-T Programmed T Cells Lysing Cells That Express Prostate Cancer Target Antigens
por: Kibel, Adam S, et al.
Publicado: (2021)

Real‐world outcomes of sipuleucel‐T treatment in PROCEED, a prospective registry of men with metastatic castration‐resistant prostate cancer
por: Higano, Celestia S., et al.
Publicado: (2019)

Sipuleucel-T immune parameters correlate with survival: an analysis of the randomized phase 3 clinical trials in men with castration-resistant prostate cancer
por: Sheikh, Nadeem A., et al.
Publicado: (2012)

A Retrospective Observational Analysis of Overall Survival with Sipuleucel-T in Medicare Beneficiaries Treated for Advanced Prostate Cancer
por: McKay, Rana R., et al.
Publicado: (2020)

Sipuleucel-T and Androgen Receptor-Directed Therapy for Castration-Resistant Prostate Cancer: A Meta-Analysis
por: Yi, Renliang, et al.
Publicado: (2016)

Sipuleucel-T: Autologous Cellular Immunotherapy for Men with Asymptomatic or Minimally Symptomatic Metastatic Castrate Resistant Prostate Cancer
por: Sims, Robert B.
Publicado: (2011)

Prolonged PSA stabilization and overall survival following sipuleucel-T monotherapy in metastatic castration-resistant prostate cancer patients
por: Holl, Eda K., et al.
Publicado: (2019)

Phase II Trial of Sipuleucel-T and Stereotactic Ablative Body Radiation for Patients with Metastatic Castrate-Resistant Prostate Cancer
por: Hannan, Raquibul, et al.
Publicado: (2022)

Immune response from STRIDE, a randomized, Phase II, open-label study of sipuleucel-T (sip-T) with concurrent vs sequential enzalutamide (enz) administration in metastatic castration-resistant prostate cancer (mCRPC)
por: Drake, Charles G, et al.
Publicado: (2015)

Survival of African-American and Caucasian men after sipuleucel-T immunotherapy: outcomes from the PROCEED registry
por: Sartor, Oliver, et al.
Publicado: (2020)

Putting the Pieces Together: Completing the Mechanism of Action Jigsaw for Sipuleucel-T
por: Madan, Ravi A, et al.
Publicado: (2020)

Sipuleucel-T for therapy of asymptomatic or minimally symptomatic, castrate-refractory prostate cancer: an update and perspective among other treatments
por: Gupta, Shilpa, et al.
Publicado: (2011)

Time to disease-related pain and first opioid use in patients with metastatic castration-resistant prostate cancer treated with sipuleucel-T
por: Small, E J, et al.
Publicado: (2014)

Phase I clinical trial of sipuleucel-T combined with escalating doses of ipilimumab in progressive metastatic castrate-resistant prostate cancer
por: Scholz, Mark, et al.
Publicado: (2017)

Real-World Effectiveness of Sipuleucel-T on Overall Survival in Men with Advanced Prostate Cancer Treated with Androgen Receptor-Targeting Agents
por: Hafron, Jason M., et al.
Publicado: (2022)

Prime-boost vaccination targeting prostatic acid phosphatase (PAP) in patients with metastatic castration-resistant prostate cancer (mCRPC) using Sipuleucel-T and a DNA vaccine
por: Wargowski, Ellen, et al.
Publicado: (2018)

Clinical use of cabozantinib in the treatment of advanced kidney cancer: efficacy, safety, and patient selection
por: Yu, Steven S, et al.
Publicado: (2016)

Bone-targeted therapies to reduce skeletal morbidity in prostate cancer
por: Dorff, Tanya B, et al.
Publicado: (2018)

Cardiovascular Toxicity During Advanced Prostate Cancer Treatment: Minding the Heart
por: Dorff, Tanya, et al.
Publicado: (2023)

Induction of antigen spread after sipuleucel-T treatment and its association with improved clinical outcome
por: GuhaThakurta, Debraj, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_o6jiu9otp19io5q126lfvsas3j